Our clinical trials are hand selected by Dr. Khurana, targeting prevention of any major cardiac event and aggressive lipid lowering treatments. These investigational medications are all unique in nature and differ from the widely used treatments you’ve heard about in the past. If you’ve had a heart attack, know someone who has, or just want to do everything you can to prevent one yourself our trials might be right for you!
Interested in hearing more about the current studies? Wondering if you qualify to participate? Contact us using the link below and the research team will get back to you soon!
Active Studies Currently Enrolling
**NEW** HERMES: Effects of ziltivekimab on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. Enrollment beginning in the Fall of 2023
**NEW** MERCK: An oral pcsk9 trial on reducing Major Adverse Cardiovascular Events in participants at high cardiovascular risk. Enrollment begins Oct 2023.
PREVAIL: An outcomes trial evaluating the effectiveness of obiceptrapib in patients with artherosclerotic cardiovascular disease that are not adequately controlled despite taking the maximally tolerated statin or lipid modifying therapy.
Ocean(a): A study of patients to summarize the distribution of lipoprotein(a) in patients with documented history of a heart attack or coronary intervention.
ZEUS: A study investigating the use of ziltivekimab on the reduction of inflammation and lowering of cardiovascular risk in patients with chronic kidney disease and atherosclerotic cardiovascular disease.
FINE-REAL: A registry of patients providing insight into the use of finerenone in routine clinical settings.
VICTORION 2: A study to analyze the impact of inclisiran on major cardiovascular events in patients with established cardiovascular disease.
Completed Studies (Not currently recruiting)
CLEAR – outcomes